Immunotech Biopharm Ltd Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
2
Price Target
HK$0.00
Consensus
-
Upside
0.00%
Analysts
0
Stock Rating
2
Upside
0.00%
Analysts
0
Price Target
HK$0.00
-

Immunotech Biopharm Ltd Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Immunotech Biopharm Ltd's Price has grown from HK$0.00 to HK$0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach HK$0.00 – an increase of 100.00%. Over the next nine years, the forecast is for Fair Value to grow by 100.00%.

2022 Fair Value Forecast
HK$0.00
2023 Fair Value Forecast
HK$0.00
2024 Fair Value Forecast
HK$0.00
2025 Fair Value Forecast
HK$0.00
2026 Fair Value Forecast
HK$0.00
2027 Fair Value Forecast
HK$0.00
2028 Fair Value Forecast
HK$0.00
2029 Fair Value Forecast
HK$0.00
2030 Fair Value Forecast
HK$0.00

Immunotech Biopharm Ltd Revenue Forecast for 2023 - 2025 - 2030

Immunotech Biopharm Ltd Dividend per Share Forecast for 2023 - 2025 - 2030

Immunotech Biopharm Ltd Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last year, Immunotech Biopharm Ltd's Free Cash Flow has grown, rising from HK$-109.23M to HK$-288.71M – a growth of 164.31%. According to 0 prominent analysts, Immunotech Biopharm Ltd's Free Cash Flow will fall by 62.17% in the next year, reaching HK$-109.22M. By 2030, professionals believe that Immunotech Biopharm Ltd's Free Cash Flow will decrease by 13.41%, reaching HK$-250.00M – a concerning trend for the company.

2021 FCF Forecast
HK$-109218993.00
2022 FCF Forecast
HK$-206245505.75
2023 FCF Forecast
HK$-244146554.85
2024 FCF Forecast
HK$-326977342.70
2025 FCF Forecast
HK$-231183880.53
2026 FCF Forecast
HK$-231638542.16
2027 FCF Forecast
HK$-243923106.18
2028 FCF Forecast
HK$-273356494.33
2029 FCF Forecast
HK$-258768369.42
2030 FCF Forecast
HK$-249996121.69

Immunotech Biopharm Ltd Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Immunotech Biopharm Ltd's Net Income has grown by 225.57%, rising from HK$-108.80M to HK$-354.22M. For the next year, 0 analysts project Immunotech Biopharm Ltd's Net Income to drop by 9.11%, reaching HK$-321.96M. By 2030, professionals believe that Immunotech Biopharm Ltd's Net Income will decrease by 7.47%, reaching HK$-327.77M – a concerning trend for the company.

2022 NI Forecast
HK$-321962365.33
2023 NI Forecast
HK$-277692540.10
2024 NI Forecast
HK$-323891322.35
2025 NI Forecast
HK$-336523083.93
2026 NI Forecast
HK$-334201074.65
2027 NI Forecast
HK$-314906532.60
2028 NI Forecast
HK$-318129076.12
2029 NI Forecast
HK$-324290175.90
2030 NI Forecast
HK$-327770890.45

Immunotech Biopharm Ltd EBITDA Forecast for 2023 - 2025 - 2030

Immunotech Biopharm Ltd's EBITDA has grown In the last two years, rising from HK$-86.79M to HK$-331.41M – a growth of 281.85%. In the following year, 0 experts forecast Immunotech Biopharm Ltd's EBITDA will decrease by 24.15%, to HK$-251.37M. In 2030, professionals predict that Immunotech Biopharm Ltd's EBITDA will decrease by 19.75%, to HK$-265.96M.

2022 EBITDA Forecast
HK$-251374485.00
2023 EBITDA Forecast
HK$-216693185.22
2024 EBITDA Forecast
HK$-251811927.44
2025 EBITDA Forecast
HK$-280258281.51
2026 EBITDA Forecast
HK$-272691307.91
2027 EBITDA Forecast
HK$-253302955.91
2028 EBITDA Forecast
HK$-253530928.57
2029 EBITDA Forecast
HK$-262260843.55
2030 EBITDA Forecast
HK$-265958721.44

Immunotech Biopharm Ltd EBIT Forecast for 2023 - 2025 - 2030

Immunotech Biopharm Ltd's EBIT has seen impressive growth In the last two years, rising from HK$-97.73M to HK$-345.15M – a growth of 253.17%. According to 0 major analysts, Immunotech Biopharm Ltd's EBIT will fall by 23.47% in the next year, reaching HK$-264.14M. Professionals believe that By 2030, Immunotech Biopharm Ltd's EBIT will fall to HK$-278.67M– a 19.26% decrease from its current value.

2022 EBIT Forecast
HK$-264143295.00
2023 EBIT Forecast
HK$-228501559.73
2024 EBIT Forecast
HK$-264307754.14
2025 EBIT Forecast
HK$-293134919.86
2026 EBIT Forecast
HK$-285532954.27
2027 EBIT Forecast
HK$-265812144.89
2028 EBIT Forecast
HK$-266033655.01
2029 EBIT Forecast
HK$-274901443.51
2030 EBIT Forecast
HK$-278667593.29

Immunotech Biopharm Ltd EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Immunotech Biopharm Ltd's EPS has grown from HK$-0.29 to HK$-0.69 – a 137.93% increase. Next year, analysts are expecting EPS to reach HK$-0.73 – an increase of 5.42%. Over the next nine years, the forecast is for EPS to grow by 6.37%.

2022 EPS Forecast
HK$-0.73
2023 EPS Forecast
HK$-0.65
2024 EPS Forecast
HK$-0.76
2025 EPS Forecast
HK$-0.74
2026 EPS Forecast
HK$-0.74
2027 EPS Forecast
HK$-0.71
2028 EPS Forecast
HK$-0.73
2029 EPS Forecast
HK$-0.73
2030 EPS Forecast
HK$-0.73